Skip to main content

Does the Hormone Neurotensin Hold the Key to a Longer Life?

New research identifies blood biomarker as decisive link between fat intake and risk for cardiovascular disesases, diabetes and obesity; spingotec‘s revolutionary sphingotest®pro-NT test measures neurotensin levels to help prevent certain diseases

Hennigsdorf, Germany – May 12, 2016

Excess weight and obesity, as well as the cardiovascular diseases and diabetes that these conditions are associated with, rank among the most widespread conditions in the world's most developed countries. In the U.S. alone, nearly 70 percent of the population is overweight and 35 percent is obese, according to the World Health Organiztion. In an article published in the scientific journal , Swedish and U.S. researchers demonstrate the link for the very first time between neurotensin values and the development of obesity. The hormone neurotensin can show when men and women of normal weight are at risk of becoming overweight and developing the diseases associated with carrying excess weight.

Researchers at the University of Malmö in Sweden have already used two major population studies to show the link between an increased concentration of the hormone neurotensin and the risk of developing certain diseases, in particular, cardiovascular diseases, diabetes and breast cancer. Now, in their latest article published in Nature, Swedish and U.S. researchers have proven that the level of neurotensin in the blood indicates whether individuals of normal weight could become obese.

Their work shows that neurotensin holds the key to how individuals utilize and absorb fat. Long known as the "fat insulin," neurotensin is released in the small intestine, particularly when animal fats are consumed. The results now published in Nature show that neurotensin is the decisive link between fat intake and the risk of developing certain diseases. People with a low fasting level of neurotensin tend not to become obese despite consuming fat and have a low risk of developing cardiovascular diseases, diabetes and breast cancer.

Researchers at biotechnology company sphingotec in Henningsdorf, Germany, have developed the sphingotest® pro-NT test that allows blood levels of neurotensin to be measured for the first time.

"Unlike genetic factors, the concentration of neurotensin in the blood is a variable that can change depending on eating habits and other lifestyle factors," explains Dr. Andreas Bergmann, founder and owner of sphingotec. "People with a low neurotensin level have a better chance of living longer and staying healthy."

Neurotensin levels can be measured as part of routine diagnostic processes using the sphingotest® pro-NT test, which is evaluated in labs using a fasting EDTA blood sample and a standard laboratory immunodiagnostic procedure (Immunoassay). For more on sphingotec and its sphingotest® pro-NT test, please visit

About sphingotec:
The biotechnology company SphingoTec GmbH, headquartered in Hennigsdorf, Germany was founded in 2002. sphingotec aims to reduce or eliminate the risk of serious diseases such as cancer, cardiovascular diseases and kidney conditions. The process starts before the disease has actually developed: using biomarkers to indicate susceptibility for a specific disease provides healthy individuals with the knowledge that they are at risk. What makes the approach so special is that the biomarkers also create a starting point for preventative strategies at the same time, as evidence-based recommendations on how to reduce risks are always an integral part of the complete concept. Further information can be found on our website at